Skip to navigation Skip to content

Clinical Trial: Comparing Experimental Fenebrutinib to Aubagio® in Relapsing MS

Share

Details
Type of MS: RRMS|SPMS
Treatment mode of action: To affect immune function
Number of Subjects: 1468
Medication: Fenebrutinib, Aubagio
Location: Alabama|Arizona|California|Colorado|District of Columbia|Florida|Indiana|Kansas|Louisiana|Michigan|Ohio|Oklahoma|South Carolina|Tennessee|Texas|Virginia|Washington
Institutions: Multiple, worldwide Contact Information
Please see below for contact information.

Funding:

 F. Hoffmann-La Roche

Description

 Investigators in the U.S. and abroad are recruiting a total of 1468 people with relapsing forms of MS for two separate studies comparing investigational oral fenebrutinib with Aubagio® (teriflunomide, Sanofi Genzyme). The studies – also called FENhance – are sponsored by F. Hoffmann-La Roche. Read more

Contact: To learn more about the enrollment criteria for this study, and to find out if you are eligible to participate, please visit study website at www.fenstudies.com, call 888-662-6728 or email global-roche-genentech-trials@gene.com.

Share


© 2022 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.